Ignite Creation Date:
2024-05-05 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00304616
Status:
COMPLETED
Last Update Posted:
2009-12-17
First Post:
2006-03-17
Brief Title:
SWitching to Abilify Trial SWAT
Sponsor:
Korea Otsuka Pharmaceutical Co Ltd
Organization:
Korea Otsuka Pharmaceutical Co Ltd
Study Overview
Official Title:
A Multi-center Randomized Open Treatment-switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy safety and tolerance of an 12 and 26-week aripiprazole administration
Detailed Description:
This trial was designed to evaluate the efficacy safety and tolerance of an 12 and 26-week aripiprazole administration to schizophrenic outpatients who maintain stable no change with dosage usage route of the most recent antipsychotic drugs symptoms and discontinued previous antipsychotic drugs
Aripiprazole 1030 mgday will be orally administered for 12 weeks followed by an extension phase for a maximum of an additional 14 weeks total of 26 weeks
Aripiprazole 1030 mgday will be orally administered for 12 weeks followed by an extension phase for a maximum of an additional 14 weeks total of 26 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None